Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group.
作者： G N Hortobagyi , R L Theriault , A Lipton , L Porter , D Blayney
DOI: 10.1200/JCO.1998.16.6.2038
关键词:
摘要: PURPOSEPamidronate, an aminobisphosphonate, has been shown to lower the risk of skeletal complications associated with lytic bone lesions for up 1 year in women stage IV breast cancer who received chemotherapy. We studied long-term effectiveness and safety continued treatment intravenous pamidronate infusions 2 years.PATIENTS AND METHODSThree hundred eighty-two metastatic chemotherapy were randomly assigned receive either 90 mg or placebo intravenously every 3 4 weeks this double-blind, multicenter, parallel-group trial. Patients evaluated monthly years complications, which included pathologic fractures, need radiation surgery treat spinal cord compression, hypercalcemia. Bone pain, analgesic use, biochemical markers, performance status, quality life, radiologic response bone, survival also evaluated.RESULTSAs th...
elsevier.com
sci-hub.se 参考文章(12)
Oliver Howard Beahrs, Max H. Myers, Manual for Staging of Cancer ,(1992)
Walter O. Spitzer, Annette J. Dobson, Jane Hall, Esther Chesterman, John Levi, Richard Shepherd, Renaldo N. Battista, Barry R. Catchlove, Measuring the quality of life of cancer patients: a concise QL-index for use by physicians. Journal of Chronic Diseases. ,vol. 34, pp. 585- 597 ,(1981) , 10.1016/0021-9681(81)90058-8
Donna Glover, Alan Lipton, Alan Keller, Antonius A. Miller, Scott Browning, Robert J. Fram, Sebastian George, Kenneth Zelenakas, Richard S. Macerata, John J. Seaman, Intravenous pamidronate disodium treatment of bone metastases in patients with breast cancer. A dose-seeking study. Cancer. ,vol. 74, pp. 2949- 2955 ,(1994) , 10.1002/1097-0142(19941201)74:11<2949::AID-CNCR2820741110>3.0.CO;2-Q
Samuel R. Nussbaum, Jerry Younger, Christine J. Vandepol, Robert F. Gagel, Mary Anne Zubler, Robert Chapman, I.Craig Henderson, Lawrence E. Mallette, Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: Comparison of 30-, 60-, and 90-mg dosages The American Journal of Medicine. ,vol. 95, pp. 297- 304 ,(1993) , 10.1016/0002-9343(93)90282-T
A. Jung, S. Bisaz, H. Fleisch, The binding of pyrophosphate and two diphosphonates by hydroxyapatite crystals. Calcified Tissue International. ,vol. 11, pp. 269- 280 ,(1973) , 10.1007/BF02547227
Adrienne M. Flanagan, Timothy J. Chambers, Inhibition of bone resorption by bisphosphonates: interactions between bisphosphonates, osteoclasts, and bone. Calcified Tissue International. ,vol. 49, pp. 407- 415 ,(1991) , 10.1007/BF02555852
A. L. Cameron, V. H. Wong, K. S. Egan, W. M. O'Fallon, B. L. Riggs, E. G. Lufkin, R. Argueta, M. D. Whitaker, Pamidronate: an unrecognized problem in gastrointestinal tolerability. Osteoporosis International. ,vol. 4, pp. 320- 322 ,(1994) , 10.1007/BF01622190
Daphne Tong, Laurence Gillick, Frank R. Hendrickson, The palliation of symptomatic osseous metastases final results of the study by the radiation therapy oncology group Cancer. ,vol. 50, pp. 893- 899 ,(1982) , 10.1002/1097-0142(19820901)50:5<893::AID-CNCR2820500515>3.0.CO;2-Y
A T van Holten-Verzantvoort, H M Kroon, O L Bijvoet, F J Cleton, L V Beex, G Blijham, J Hermans, J P Neijt, S E Papapoulos, H P Sleeboom, Palliative pamidronate treatment in patients with bone metastases from breast cancer. Journal of Clinical Oncology. ,vol. 11, pp. 491- 498 ,(1993) , 10.1200/JCO.1993.11.3.491
R Gucalp, P Ritch, P H Wiernik, P R Sarma, A Keller, S P Richman, K Tauer, J Neidhart, L E Mallette, R Siegel, Comparative study of pamidronate disodium and etidronate disodium in the treatment of cancer-related hypercalcemia. Journal of Clinical Oncology. ,vol. 10, pp. 134- 142 ,(1992) , 10.1200/JCO.1992.10.1.134